Abstract

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are inflammatory diseases of the central nervous system. Although several studies have characterized the metabolome in the cerebrospinal fluid (CSF) from MS and NMOSD patients, comparative analyses between them and between the relapse and the remission of each disease have not been performed. Both univariate and multivariate analyses were used to compare 1H-NMR spectra of CSF from MS, NMOSD, and healthy controls (HCs). The statistical analysis showed alterations of eight metabolites that were dependent on the disease. Levels of 2-hydroxybutyrate, acetone, formate, and pyroglutamate were higher and levels of acetate and glucose were lower in both MS and NMOSD. Citrate was lower in MS patients, whereas lactate was higher in only NMOSD specifically. The shared feature of metabolic changes between MS and NMOSD may be related to altered energy metabolism and fatty acid biosynthesis in the brain. Another analysis to characterize relapse and remission status showed that isoleucine and valine were down-regulated in MS relapse compared to MS remission. The other metabolites identified in the disease comparison showed the same alterations regardless of disease activity. These findings would be helpful in understanding the biological background of these diseases, and distinguishing between MS and NMOSD, as well as determining the disease activity.

Highlights

  • Multiple sclerosis (MS) is the most common autoimmune demyelinating disease of the central nervous system (CNS) affecting more than two million people around the world [1]

  • We aimed to identify similar and different metabolic features between MS and neuromyelitis optica spectrum disorder (NMOSD) and to identify those metabolites that might characterize disease activity using an Nuclear magnetic resonance (NMR) based metabolomics approach

  • A 1H NMR spectrum was acquired for each of the 124 cerebrospinal fluid (CSF) samples collected from 17 healthy controls (HCs), 50 (Relapse 20 and Remission 30) MS patients and 57 NMOSD patients (Relapse 36 and Remission 21) (Table 1)

Read more

Summary

Introduction

Multiple sclerosis (MS) is the most common autoimmune demyelinating disease of the central nervous system (CNS) affecting more than two million people around the world [1].

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.